Prof Patrick Rossignol (Centre d'Investigations Cliniques, CHRU de Nancy, Vandoeuvre-lès-Nancy, FR) discusses the Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER) Trial - Results in the Prespecified Subgroup with Heart Failure.

Filmed on site at HFA 2019 by Radcliffe Cardiology.

Videography: Mike Knight & Tom Green

Interviewer: Liam O'Neill